NewsBenzinga周六报告：艾伯维表示，Rinvoq在第144周约四年时维持克罗恩病内镜缓解率达47.1%-64.2%；Skyrizi在UEGW上显示溃疡性结肠炎于第96周维持内镜缓解率达38.8%-53.5% 周六报告：艾伯维表示，Rinvoq在第144周约四年时维持克罗恩病内镜缓解率达47.1%-64.2%；Skyrizi在UEGW上显示溃疡性结肠炎于第96周维持内镜缓解率达38.8%-53.5% Benzinga 2026.10.19 07:01 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Overweight on Essential Properties, Lowers Price Target to $30 Morgan Stanley Maintains Equal-Weight on Sportradar Gr, Lowers Price Target to $13.5 Morgan Stanley Maintains Underweight on Simmons First Ntl, Raises Price Target to $27 Wells Fargo Maintains Equal-Weight on EPR Properties, Lowers Price Target to $56 Analyst Sees Billions in Walmart's Next Big Advertising Opportunity Morgan Stanley Maintains Equal-Weight on Red Rock Resorts, Lowers Price Target to $59
